Thomas Allen Net Worth

Thomas Allen biography

Thomas Allen serves as Independent Director of the Company. Mr. Allen has served as Managing Director, Advent International Ltd, an affiliate of Advent focusing on investments in the healthcare sector, since 2014. He has worked at Advent since 2004. Prior to joining Advent, he worked at Arthur Andersen and KPMG as part of the firms’ London private equity teams. Mr. Allen is currently a member of the board of Mediq, a provider of medical devices and care solutions, and a member of the board of Advent International Ltd. Mr. Allen is also on the board of directors of Zentiva Group, a leading European generics pharmaceutical company, where he serves on the Advisory Committee and Remuneration Committee, and GLOBAL MENSA S.L., the holding company of Vitaldent, a Spanish network of dental care clinics. Mr. Allen previously served on the board of Priory Group. Mr. Allen received his Bachelor of Arts degree in economics from the University of Manchester and is a qualified accountant.

What is the salary of Thomas Allen?

As the Independent Director of Syneos Health Inc, the total compensation of Thomas Allen at Syneos Health Inc is $90,000. There are 18 executives at Syneos Health Inc getting paid more, with Alistair Macdonald having the highest compensation of $7,646,360.

How old is Thomas Allen?

Thomas Allen is 42, he's been the Independent Director of Syneos Health Inc since 2017. There are 21 older and no younger executives at Syneos Health Inc. The oldest executive at Syneos Health Inc is William Klitgaard, 67, who is the Independent Director.

Insiders trading at Syneos Health Inc

Over the last 7 years, insiders at Syneos Health Inc have traded over $16,280,601,287 worth of Syneos Health Inc stock and bought 17,946 units worth $873,496 . The most active insiders traders include Todd M Abbrecht, John L. Maldonado a Tom Allen. On average, Syneos Health Inc executives and independent directors trade stock every 14 days with the average trade being worth of $83,067,962. The most recent stock trade was executed by Michael Lee Brooks on 28 July 2022, trading 1,502 units of SYNH stock currently worth $117,156.

What does Syneos Health Inc do?

inc research/inventiv health has become syneos health, the only fully integrated end-to-end clinical and commercial solution organization. we are purpose-built for biopharmaceutical acceleration, creating better, smarter, faster ways to help clients navigate an increasingly complex marketplace. our new business addresses today’s market realities through clinical and commercial sharing expertise and data and insights to meet the needs of emerging and large global biopharmaceutical companies.

Syneos Health Inc executives and stock owners

Syneos Health Inc executives and other stock owners filed with the SEC include:

• Alistair Macdonald,
  Chief Executive Officer, Director
• Jason Meggs,
  Chief Financial Officer
• Paul Colvin,
  President - Clinical Solutions
• Michelle Keefe,
  President - Commercial Solutions
• Jonathan Olefson,
  General Counsel, Corporate Secretary
• Alistair Macdonald,
  CEO & Director
• Jason M. Meggs,
  Chief Financial Officer
• Paul D. Colvin,
  Chief Bus. Officer
• Michelle Keefe,
  Pres of Commercial Solutions
• Jonathan Olefson,
  Gen. Counsel & Corp. Sec.
• John Dineen,
  Independent Chairman of the Board
• William Klitgaard,
  Independent Director
• Kenneth Meyers,
  Independent Director
• Linda Harty,
  Independent Director
• Matthew Monaghan,
  Independent Director
• Joshua Nelson,
  Independent Director
• Todd Abbrecht,
  Independent Director
• Bernadette Connaughton,
  Independent Director
• Thomas Allen,
  Independent Director
• John Maldonado,
  Independent Director
• Ronnie Speight,
  Senior Vice President, Investor Relations
• Robert Parks,
  Executive Vice President, Chief Accounting Officer
• Lisa van Capelle,
  Chief Human Resource Officer
• Dr. Judith Ng-Cashin M.D.,
  Chief Scientific Officer
• Kristen Spensieri,
  Global Head of Corp. Communications & Marketing
• Larry A. Pickett Jr.,
  Chief Information & Digital Officer
• Dr. Judith Ng-Cashin,
  Chief Scientific Officer
• Donna Hildebrand Kralowetz,
  Sr. VP of Fin. & Principal Accounting Officer
• H. Lee Advisors, Llcthl Fun...,
  
• International Corp/Maap Gpe...,
  
• International Corp/Ma Doubl...,
  
• Tom Allen,
  
• International Corp/Ma Adven...,
  
• International Corp/Ma Adven...,
  
• International Corp/Ma Adven...,
  
• International Corp/Ma Adven...,
  
• International Corp/Ma Adven...,
  
• Christopher L Gaenzle,
  CAO, GC & Sec
• Michael Adam Bell,
  Director
• Joshua M Nelson,
  
• Todd M Abbrecht,
  
• H. Lee Advisors, Llcthl Hol...,
  
• H. Lee Advisors, Llc Thomas...,
  
• International Corp/Ma Adven...,
  
• H. Lee Advisors, Llc Thomas...,
  
• H. Lee Advisors, Llcthl Fun...,
  
• H. Lee Equity Fund Vi, L.P....,
  
• Christian Tucat,
  Chief Business Officer
• Michael Lee Brooks,
  Chief Operating Officer
• Barbara W. Bodem,
  Director
• Alfonso G Zulueta,
  Director
• Stanford Rudnick,
  See remarks
• International Corp/Ma Adven...,
  
• International Corp/Ma Adven...,
  
• International Corp/Ma Adven...,
  
• Michael J. Bonello,
  Chief Financial Officer
• Donna Hildebrand Kralowetz,
  EVP, Chief Accounting Officer
• International Corp/Ma Adven...,
  
• International Corp/Ma Adven...,
  
• International Corp/Ma Adven...,
  
• H. Lee Advisors, Llcthl Fun...,
  
• International Corp/Maap Gpe...,
  
• International Corp/Maap Gpe...,
  
• David S. Wilkes,
  Director